Q3 EPS Forecast for Palvella Therapeutics Lowered by Analyst

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Equities research analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for shares of Palvella Therapeutics in a report released on Wednesday, August 5th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($1.98) per share for the quarter, down from their previous estimate of ($1.69). HC Wainwright has a “Buy” rating and a $270.00 price objective on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($5.58) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ Q4 2026 earnings at ($2.05) EPS, FY2026 earnings at ($6.79) EPS, FY2027 earnings at ($7.43) EPS, FY2028 earnings at ($0.83) EPS, FY2029 earnings at $6.18 EPS and FY2030 earnings at $19.10 EPS.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35).

A number of other research firms have also recently weighed in on PVLA. Canaccord Genuity Group set a $232.00 price objective on shares of Palvella Therapeutics in a report on Wednesday. Wall Street Zen lowered shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Truist Financial set a $207.00 target price on Palvella Therapeutics in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Finally, Stephens reaffirmed an “overweight” rating and issued a $220.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $209.14.

Palvella Therapeutics Stock Performance

Shares of NASDAQ PVLA opened at $154.93 on Friday. The company’s fifty day moving average price is $132.97 and its 200 day moving average price is $119.75. Palvella Therapeutics has a 1 year low of $37.33 and a 1 year high of $161.38. The company has a market capitalization of $2.23 billion, a PE ratio of -32.08 and a beta of -0.17.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the sale, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. The trade was a 66.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.20% of the company’s stock.

Institutional Trading of Palvella Therapeutics

Several institutional investors have recently modified their holdings of PVLA. First Light Asset Management LLC increased its stake in shares of Palvella Therapeutics by 38.3% during the first quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock worth $122,251,000 after purchasing an additional 271,617 shares in the last quarter. Suvretta Capital Management LLC lifted its stake in Palvella Therapeutics by 8.5% in the 4th quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock valued at $93,408,000 after buying an additional 70,000 shares in the last quarter. Jennison Associates LLC lifted its stake in Palvella Therapeutics by 65.3% in the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock valued at $79,852,000 after buying an additional 253,128 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Palvella Therapeutics by 13.3% in the 4th quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock worth $58,680,000 after buying an additional 65,960 shares during the last quarter. Finally, State Street Corp boosted its holdings in Palvella Therapeutics by 206.3% in the 4th quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after buying an additional 283,211 shares during the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.